JP2008526188A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526188A5
JP2008526188A5 JP2007548837A JP2007548837A JP2008526188A5 JP 2008526188 A5 JP2008526188 A5 JP 2008526188A5 JP 2007548837 A JP2007548837 A JP 2007548837A JP 2007548837 A JP2007548837 A JP 2007548837A JP 2008526188 A5 JP2008526188 A5 JP 2008526188A5
Authority
JP
Japan
Prior art keywords
use according
protein
promoter
nucleic acid
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007548837A
Other languages
English (en)
Japanese (ja)
Other versions
JP5584393B2 (ja
JP2008526188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/000009 external-priority patent/WO2006070023A2/en
Publication of JP2008526188A publication Critical patent/JP2008526188A/ja
Publication of JP2008526188A5 publication Critical patent/JP2008526188A5/ja
Application granted granted Critical
Publication of JP5584393B2 publication Critical patent/JP5584393B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007548837A 2004-12-31 2006-01-02 動物細胞における多剤耐性を逆転させる方法 Expired - Fee Related JP5584393B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102004063639 2004-12-31
DE102004063639.7 2004-12-31
US65108505P 2005-02-08 2005-02-08
US60/651,085 2005-02-08
PCT/EP2006/000009 WO2006070023A2 (en) 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells

Publications (3)

Publication Number Publication Date
JP2008526188A JP2008526188A (ja) 2008-07-24
JP2008526188A5 true JP2008526188A5 (https=) 2009-02-19
JP5584393B2 JP5584393B2 (ja) 2014-09-03

Family

ID=36582063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007548837A Expired - Fee Related JP5584393B2 (ja) 2004-12-31 2006-01-02 動物細胞における多剤耐性を逆転させる方法

Country Status (10)

Country Link
US (4) US20100310554A1 (https=)
EP (1) EP1831382B1 (https=)
JP (1) JP5584393B2 (https=)
KR (1) KR101527213B1 (https=)
CN (1) CN101128593B (https=)
AU (1) AU2006203736B2 (https=)
CA (1) CA2592699C (https=)
MX (1) MX2007008136A (https=)
SG (1) SG158133A1 (https=)
WO (1) WO2006070023A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487811A1 (en) 2002-05-27 2003-12-04 Per Sonne Holm Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
WO2010068794A2 (en) * 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
CA2863964C (en) * 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
US10202568B2 (en) 2013-08-12 2019-02-12 Invivosciences Inc. Automated cell culture system and method
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US10813957B2 (en) * 2016-10-07 2020-10-27 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
US20200155625A1 (en) * 2017-05-24 2020-05-21 Epicentrx, Inc. Anti-angiogenic adenovirus
CN109576231B (zh) 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
CN113774031B (zh) * 2020-06-10 2024-04-02 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用
EP4410971A4 (en) * 2021-09-30 2025-06-04 FUJIFILM Corporation METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU718772B2 (en) * 1995-03-24 2000-04-20 Genzyme Corporation Adenovirus vectors for gene therapy
US6228646B1 (en) * 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
ES2210081T3 (es) * 1998-07-07 2004-07-01 Transgene S.A. Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.
WO2000029573A2 (en) * 1998-11-18 2000-05-25 Canji, Inc. Adenoviral vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
WO2001002556A2 (de) * 1999-06-30 2001-01-11 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur diagnose, prognose und therapie maligner erkrankungen
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
WO2001028569A1 (en) * 1999-10-15 2001-04-26 Canji, Inc. Targeted vectors
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
EP1446479B1 (en) * 2001-09-29 2012-08-15 Chae-Ok Yun Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
DK1497440T3 (da) * 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
CA2487811A1 (en) * 2002-05-27 2003-12-04 Per Sonne Holm Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
EP1554375B1 (de) * 2002-10-15 2018-08-22 Per Sonne Holm Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
RU2393221C2 (ru) * 2002-10-15 2010-06-27 Пер Сонне ХОЛЬМ Аденовирус с обращенной генной экспрессией и его применение
WO2004083244A2 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Specific inhibition of allograft rejection
JP4871726B2 (ja) * 2003-04-28 2012-02-08 ナノシス・インク． 超疎液性表面、その作製法及び用途
EP1689446B1 (de) * 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus

Similar Documents

Publication Publication Date Title
JP2008526188A5 (https=)
US11268073B2 (en) Use of adenovirus and nucleic acids coding therefor
KR101396454B1 (ko) 내피 세포 특이성을 나타내는 프로모터 및 이를 이용하여 혈관신생을 조절하는 방법
Zhu et al. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo
KR102229084B1 (ko) 아데노바이러스를 사용하는 치료 방법
US20100311145A1 (en) Novel use of adenoviruses and nucleic acids that code for said viruses
US20100151576A1 (en) Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
JP2007511212A5 (https=)
JP2008526189A5 (https=)
JP2004500880A (ja) 肝臓特異的な遺伝子発現カセット、及びその使用法
JP2011200234A (ja) 新規アデノウイルス、それをコードする核酸及びその使用
JP2006512284A5 (https=)
JP5435871B2 (ja) Ｅ１−マイナスアデノウイルス及びその使用
JP5584393B2 (ja) 動物細胞における多剤耐性を逆転させる方法
US20040242523A1 (en) Chemo-inducible cancer gene therapy
WO2012022496A2 (en) Method for killing tumor stem cells
Hodish et al. Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK
JP2005530495A (ja) オールターナティブスプライシングされる核酸分子
AU2015201828B2 (en) Novel use of adenoviruses and nucleic acids coding therefor
CN1705740B (zh) 具有反向基因表达的腺病毒及其应用
Parikh et al. 294. Herpes Simplex Virus Mediated Oncolysis is an Effective Intratumoral Therapy in High-Risk Neuroblastoma Tumor Models
RU2004138095A (ru) Новое применение аденовируса и кодирующих его нуклеиновых кислот
Ramsay Cancer treatment involving the p53 gene